Non-small cell lung cancer Archives -

AZ takes aim at BMS’ lead in neoadjuvant NSCLC

Phil Taylor AstraZeneca, Bristol-Myers Squibb, Imfinzi, immuno-oncology, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology, Opdivo 0 Comment

Just weeks after Bristol-Myers Squibb claimed an FDA green light for Opdivo as a neoadjuvant therapy for non-small

AZ takes aim at BMS’ lead in neoadjuvant NSCLC

https://pharmaphorum.com/news/az-takes-aim-at-bms-lead-in-neoadjuvant-nsclc/

News/ News/ Oncology

Roche’s Tecentriq extends lead over Keytruda in adjuvant NSCLC

Phil Taylor adjuvant, immuno-oncology, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology, regulatory approval, Roche, Tecentriq 0 Comment

While Merck & Co’s Keytruda is the undisputed leader of the non-small cell lung cancer (NSCLC) category, there’s

Roche’s Tecentriq extends lead over Keytruda in adjuvant NSCLC

https://pharmaphorum.com/news/roches-tecentriq-extends-lead-over-keytruda-in-adjuvant-nsclc/

News/ News/ Oncology

Mirati heads for FDA verdict on KRAS drug with new data

Phil Taylor adagrasib, Amgen, asco, KRAS, Lumakras, Mirati, Non-small cell lung cancer 0 Comment

Mirati Therapeutics will hear from the FDA on its KRAS inhibitor adagrasib later this year, hoping to compete

Mirati heads for FDA verdict on KRAS drug with new data

https://pharmaphorum.com/news/mirati-heads-for-fda-verdict-on-kras-drug-with-new-data/

News/ News/ News/ Oncology/ R&D

Roche’s TIGIT ambitions take another blow

Phil Taylor immuno-oncology, Non-small cell lung cancer, Oncology, Roche, TIGIT, tiragolumab 0 Comment

Roche’s anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its

Roche’s TIGIT ambitions take another blow

https://pharmaphorum.com/news/roches-tigit-ambitions-take-another-blow/

Market Access/ News/ News/ News/ Oncology

CHMP backs Roche’s lymphoma bispecific mosunetuzumab

Phil Taylor CHMP, immuno-oncology, mosunetuzumab, non-Hodgkin lymphoma, Non-small cell lung cancer, Oncology, Roche, Tecentriq 0 Comment

Roche is on the brink of its first regulatory approval for what could be the first bispecific antibody

CHMP backs Roche’s lymphoma bispecific mosunetuzumab

https://pharmaphorum.com/news/chmp-backs-roches-lymphoma-bispecific-mosunetuzumab/

Market Access/ News/ News/ News/ Oncology

FDA starts speedy review of Enhertu in lung cancer

Phil Taylor AstraZeneca, Daiichi Sankyo, Enhertu, her2, Non-small cell lung cancer 0 Comment

AstraZeneca and Daiichi Sankyo should only have to wait for six months to hear from the FDA if

FDA starts speedy review of Enhertu in lung cancer

https://pharmaphorum.com/news/fda-starts-speedy-review-of-enhertu-in-lung-cancer/

News/ News/ Oncology

AACR: Novartis joins the KRAS clan, eyeing swift move to phase 3

Phil Taylor Amgen, KRAS, Lumakras, Mirati, Non-small cell lung cancer, Novartis, novel targeted cancer treatments, Oncology 0 Comment

Novartis has joined the select cadre of drugmakers developing KRAS inhibitors for cancer, opening its account with phase

AACR: Novartis joins the KRAS clan, eyeing swift move to phase 3

https://pharmaphorum.com/news/aacr-novartis-joins-the-kras-clan-eyeing-swift-move-to-phase-3/

News/ News/ Oncology

EMA starts review of Novartis’ latecomer PD-1 drug tislelizumab

Phil Taylor alpelisib, immuno-oncology, Non-small cell lung cancer, Novartis, oesophageal cancer, Oncology, regulatory approval, tislelizumab 0 Comment

The EU regulator has started a review of Novartis’ PD-1 inhibitor tislelizumab – licensed from Chinese biotech BeiGene –

EMA starts review of Novartis’ latecomer PD-1 drug tislelizumab

https://pharmaphorum.com/news/ema-starts-review-of-novartis-latecomer-pd-1-drug-tislelizumab/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

Digital/ News/ News

AI test could predict best cancer therapies for patients

Phil Taylor artificial intelligence, digital, digital health, Non-small cell lung cancer, Oncology, personalised medicine 0 Comment

Researchers at the Institute of Cancer Research (ICR) in London have designed a prototype test that they think

AI test could predict best cancer therapies for patients

https://pharmaphorum.com/news/ai-test-could-predict-best-cancer-therapies-for-patients/

Trending

Non-small cell lung cancer

Login